



April 19, 2021

Fresenius Kabi USA, LLC

Three Corporate Drive
Lake Zurich, Illinois 60047
T 847-550-2300
T 888-391-6300
www.fresenius-kabi.com/us

Dear Valued Customer,

The purpose of this letter is to inform you of the impact of the Defense Production Act (DPA) on the manufacturing and supply of certain Fresenius Kabi products. Orders for certain injectables we produce have been designated (or “rated”) under the DPA. Production of rated orders requires prioritization over other production and thus may impact the availability of a limited number of other Fresenius Kabi products.

The DPA allows the President of the United States and his designees to require corporations to accept and prioritize contracts for services and materials deemed necessary for national defense. As a result of the DPA, we have had to deprioritize, as required by law, production of other essential medicines to focus on products needed for the country’s rapid vaccination deployment.

As a leading supplier of essential medicines, Fresenius Kabi has been involved in production efforts that support the response to COVID-19 since the beginning of the pandemic. Our manufacturing plants are fully operational and considered part of the essential country infrastructure responding to this crisis.

The application of the DPA is also creating interruptions for our suppliers, many of which also produce DPA-rated products. This may cause interruptions in the delivery of components and packaging materials as they are required to prioritize deliveries for the production of DPA-rated products over deliveries to Fresenius Kabi.

While we maintain safety stock for many Fresenius Kabi pharmaceutical products, it is likely that complying with the DPA will cause intermittent backorders of a small number of products.

We value your trust in us and we are committed to doing everything in our control to mitigate supply disruptions while supporting America’s unprecedented COVID-19 response efforts. For product availability updates, please visit our web site at <https://www.fresenius-kabi.com/us/pharmaceutical-product-availability> or call our Customer Service team at 1-888-386-1300, Monday–Friday between 7 a.m. and 6 p.m. (CST).

Sincerely,

A handwritten signature in cursive script that reads "Lindsey Thomas".

Lindsey Thomas
Senior Vice President, Marketing